GlobeNewsWire
13 Sept 2026, 16:00 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
A class action lawsuit alleges that the Phase III Fianlimab-Libtayo study's preliminary statistical assumptions were fundamentally flawed and unlikely to achieve its primary endpoint. — Allegations of flawed trial design and probable failure of a major Phase III study directly threaten the future revenue potential and pipeline value of a pharmaceutical company.
-0.70The lawsuit claims Regeneron's active treatment arm in the Fianlimab-Libtayo study showed no meaningful clinical differentiation from standard therapies. — Lack of clinical differentiation reduces the competitive advantage and market penetration potential of the drug upon potential approval.
-0.50A securities class action lawsuit has been filed against Regeneron Pharmaceuticals and its officers for alleged violations of federal securities laws between August 1, 2025, and May 15, 2026. — Legal proceedings create headline risk and potential financial liabilities, though securities litigation is common for large-cap biotech.
-0.30Continue reading
5 related stories
Top 1 mover · tap to explore
Which stocks this story touches
The company is the subject of a new class action lawsuit alleging securities fraud violations.
The company is the subject of a new class action lawsuit alleging securities fraud violations.
The company is facing a class action lawsuit alleging securities fraud and misleading statements regarding a Phase III clinical study.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
5h ago
